Advancing Ultraviolet Photodissociation Mass Spectrometry for Precision Mapping of Protein Glycosylation

NIH RePORTER · NIH · F31 · $37,916 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY Glycosylation plays a structural and functional role in all fundamental features of proteins in cells. Despite substantial evidence suggesting O-glycosylation is vital in cellular processes, the nature of O-linked glycans and the specific locations of O-glycans are not well characterized. To a large extent, the consensus sequence motif N-X-S/T enables reliable prediction of N-glycosylation sites, but our knowledge of O-glycosylation is hampered by a lack of simple consensus motifs. As a result, our current understanding of the impact of O-glycosylation is incomplete. A major obstacle to comprehensive characterization of O-glycosylation by mass spectrometry-based proteomic workflows is the prominent neutral loss of labile O-linked glycans using conventional collisional activated dissociation, hampering precise localization. Moreover, no global enzyme exists that can cleave every possible O-glycan β-O-glycosidic linkage, thwarting enzymatic glycomic analysis. Mass spectrometry coupled with ultraviolet photodissociation (UVPD) is positioned to be an important tool in glycoproteomics by enabling residue-level resolution of PTMs of proteins implicated in human health. UVPD can be harnessed to provide simultaneously high sequence coverage of peptides and retention of labile modifications, thus allowing O-glycan mapping and structural characterization. My development of innovative LC-UVPD-MS strategies suitable for both targeted and global glycoproteomic applications will provide new insight into the correlation of glycosylation with disease pathways and drive new biological questions.

Key facts

NIH application ID
10141782
Project number
1F31GM140595-01
Recipient
UNIVERSITY OF TEXAS AT AUSTIN
Principal Investigator
Edwin E Escobar
Activity code
F31
Funding institute
NIH
Fiscal year
2021
Award amount
$37,916
Award type
1
Project period
2021-01-01 → 2023-12-31